Lin Shen, MD
Peking University Cancer Hospital & Institute
20
20
5
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+18 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
jiafu ji, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Xiaotian Zhang, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Wen-Yang Liu, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Worked with same sponsors:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (20)
Showing 20 of 20 trials
A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
EVM16 Injection as a Single and Combination With Tislelizumab in Solid Tumors
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
The Transformation of Locally Advanced Pancreatic Cancer.
Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
All 20 trials loaded